Egalet to Present at the Cowen and Company 34th Annual Health Care Conference on March 4 - WAFF-TV: News, Weather and Sports for Huntsville, AL

Egalet to Present at the Cowen and Company 34th Annual Health Care Conference on March 4

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Egalet Corporation

WAYNE, Pa., Feb. 19, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at the 34th Annual Cowen Health Care Conference in Boston on Tuesday, March 4, 2014 at 9:20 a.m. eastern standard time. Mr. Radie will provide an overview of the company's abuse-deterrent product candidates. The presentations that will be audio webcast live and available for replay will be available at Egalet's website, http://egalet.investorroom.com/eventsandwebcasts.

(Logo:  http://photos.prnewswire.com/prnh/20140219/NY67493LOGO)

About Egalet

Egalet Corporation is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications. The company has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient. Using its proprietary platform, Egalet has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation, while also providing tailored release of the active pharmaceutical ingredient. Our lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. There are currently no commercially available abuse-deterrent formulations of morphine, and we believe that Egalet-001, if approved, would fill a significant unmet need in the marketplace. Our second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain. The Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles.  Visit www.egalet.com for more information.

Contacts:

Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
Tel: 917-543-9932
Email: lwilson@insitecony.com

Media:
E. Blair Clark-Schoeb
Tel: 917-432-9275
Email: blair@biotechcomm.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

1414 North Memorial Parkway
Huntsville, AL 35801
256-533-4848

WAFF Is a Proud Member
of the Raycom Family of Stations


FCC Public File
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WAFF. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.